FDA approves treatment for sexual dysfunction in premenopausal women
The FDA has announced its approval of a therapy for hypoactive sexual desire disorder in premenopausal women.
List view / Grid view
The FDA has announced its approval of a therapy for hypoactive sexual desire disorder in premenopausal women.
The FDA has told its staff that it will be assigning drug compounding to the Office of Compliance.
The company has announced a recall of products which were intended to be sterile after a lack of sterility assurance.
The FDA has released new data points which increase transparency for generic-drug competitors.
The FDA has given its approval to a new injection for cluster headaches which reduce frequency of attacks.
Companies that invest heavily now stand to steal a lasting lead over rivals that hesitate...
The FDA is seeking closer collaboration with state authorities to ensure the quality of compounded drugs and the public’s access to them...
This article explores how the new draft of Annex 1, Manufacture of Sterile Medicinal Products impacts environmental monitoring programmes.
The US FDA have granted the NDA for iclaprim, an antibiotic for a skin condition, Priority Review, with a decision date set for February 2019...
Boosting the safety of compounded drugs is the aim of new plan from the US Food and Drug Administration (FDA), which has unveiled a series of measures.
Researchers develop a better delivery system for anti-inflammatory therapies...
Researchers have collaborated to design a smart bandage that could eventually heal chronic wounds...